LAMTOR2 Gene

MLST8 Protein

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">LAMTOR2 Gene</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>MLST8</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MLST8</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>MTOR Associated Protein, LST8 Homolog</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q8BXR0 (Mouse), Q9BVA0 (Human)</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>84916 (Human)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~36 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Lysosomal membrane, cytoplasm</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>LST8/MLST8 family</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Ubiquitous; highest in brain, heart, skeletal muscle</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Rapamycin (Sirolimus)</td>
<td>Allosteric</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Allosteric</td>
</tr>
<tr>
<td class="label">Torin 1</td>
<td>ATP-competitive</td>
</tr>
<tr>
<td class="label">AZD8055</td>
<td>ATP-competitive</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>

Introduction

MLST8 Protein

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">LAMTOR2 Gene</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>MLST8</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MLST8</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>MTOR Associated Protein, LST8 Homolog</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q8BXR0 (Mouse), Q9BVA0 (Human)</td>
</tr>
<tr>
<td class="label">Gene ID</td>
<td>84916 (Human)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~36 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Lysosomal membrane, cytoplasm</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>LST8/MLST8 family</td>
</tr>
<tr>
<td class="label">Tissue Expression</td>
<td>Ubiquitous; highest in brain, heart, skeletal muscle</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Type</td>
</tr>
<tr>
<td class="label">Rapamycin (Sirolimus)</td>
<td>Allosteric</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Allosteric</td>
</tr>
<tr>
<td class="label">Torin 1</td>
<td>ATP-competitive</td>
</tr>
<tr>
<td class="label">AZD8055</td>
<td>ATP-competitive</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>

Introduction

MLST8 ([MTOR](/mechanisms/mtor-signaling-pathway) Associated Protein, LST8 Homolog) is a critical component of both mTORC1 and mTORC2 complexes and plays important roles in neurodegenerative diseases. This page provides comprehensive information about its structure, function, and therapeutic implications. [@discovery]

Overview

MLST8 is a conserved protein component of the mechanistic Target of Rapamycin (mTOR) kinase complexes. As a core subunit, MLST8 provides structural support and helps regulate the kinase activity of both mTORC1 and mTORC2. Targeting MLST8 and [mTOR](/entities/mtor) signaling has significant therapeutic potential in neurodegenerative diseases. [@mtor]

Protein Information

Structure

MLST8 contains several key structural features:

• WD40 Repeat Domains: Seven WD40 repeats form a beta-propeller structure that mediates protein-protein interactions
• Beta-Propeller Structure: Provides a stable scaffold for complex formation
• HEAT Repeats: Facilitate interactions with other mTOR complex components
• Phosphorylation Sites: Multiple serine/threonine phosphorylation sites regulate function

Molecular Function

MLST8 is essential for mTOR complex function and structure:

mTORC1 Function

• Structural Stabilization: Maintains mTORC1 integrity
• Kinase Activity Enhancement: Amplifies mTOR catalytic activity
• Substrate Recruitment: Facilitates substrate access to the kinase domain
• RAPTOR Interaction: Works with RAPTOR to regulate mTORC1 signaling

mTORC2 Function

• Complex Assembly: Required for proper mTORC2 formation
• Kinase Activation: Essential for mTORC2 autophosphorylation
• AKT Activation: Mediates AKT phosphorylation at Ser473
• RICTOR Interaction: Partners with RICTOR for mTORC2 function

Expression Pattern

MLST8 exhibits broad tissue expression with notable levels in the nervous system:

Brain Regions

• Cerebral [Cortex](/brain-regions/cortex): High expression in pyramidal [neurons](/entities/neurons)
• [Hippocampus](/brain-regions/hippocampus): Particularly in CA1-CA3 regions
• Cerebellum: Purkinje cells show significant expression
• Basal Ganglia: Moderate expression in striatal neurons

Cellular Localization

• Synaptic Compartments: Presynaptic terminals and postsynaptic densities
• Dendrites and Axons: Cytosolic and membrane-associated pools
• Lysosomal Membrane: Critical for mTORC1 localization
• Cytoplasm: General cytoplasmic distribution

Disease Associations

Alzheimer's Disease

MLST8 and mTOR signaling are critically involved in Alzheimer's disease pathogenesis:

• mTORC1 Hyperactivation: Elevated mTORC1 activity in AD brains correlates with cognitive decline
• [Autophagy](/entities/autophagy) Impairment: mTORC1 inhibits autophagy, leading to accumulated protein aggregates ([amyloid-beta](/proteins/amyloid-beta), tau)
• Synaptic Plasticity Deficits: mTOR dysregulation affects [long-term potentiation](/mechanisms/long-term-potentiation) ([LTP](/mechanisms/long-term-potentiation))
• Memory Impairment: mTORC1 hyperactivation impairs memory consolidation
• Therapeutic Targeting: mTOR inhibitors show promise in preclinical AD models

• PMID: 25396082(https://pubmed.ncbi.nlm.nih.gov/25396082/) - mTOR signaling in Alzheimer's disease
• PMID: 26255403(https://pubmed.ncbi.nlm.nih.gov/26255403/) - Autophagy and neurodegeneration

Parkinson's Disease

MLST8/mTOR signaling plays a complex role in PD:

• [Alpha-Synuclein](/mechanisms/alpha-synuclein) Metabolism: mTOR regulates autophagy of [alpha-synuclein](/proteins/alpha-synuclein) aggregates
• Mitochondrial Dysfunction: mTORC2/PI3K/AKT pathway affects mitochondrial health
• Dopaminergic Neuron Survival: mTOR activity influences neuronal viability
• LRRK2 Interaction: G2019S LRRK2 mutation affects mTOR signaling

• PMID: 26925799(https://pubmed.ncbi.nlm.nih.gov/26925799/) - mTOR in Parkinson's disease models
• PMID: 28749530(https://pubmed.ncbi.nlm.nih.gov/28749530/) - Autophagy and alpha-synuclein

Tuberous Sclerosis Complex (TSC)

• mTORC1 Hyperactivation: TSC1/TSC2 mutations cause constitutive mTORC1 activation
• Neurological Manifestations: Seizures, intellectual disability, autism
• Rapamycin Treatment: mTOR inhibitors effectively reduce tumor growth and seizures

Amyotrophic Lateral Sclerosis (ALS)

• mTOR Dysregulation: Observed in ALS patient tissues and models
• Autophagy Defects: Impaired clearance of mutant proteins (SOD1, FUS, TDP-43)
• Therapeutic Potential: mTOR modulation may benefit ALS patients

Signaling Pathways

mTORC1 Pathway

Amino Acids → Rag GTPases → mTORC1 (RAPTOR) → S6K1/4E-BP1
↓
Protein Synthesis, Autophagy

mTORC2 Pathway

Growth Factors → PI3K → PDK1 → AKT → mTORC2 (RICTOR)
↓
AKT (Ser473), PKCα, SGK1

Therapeutic Implications

mTOR Inhibitors

Autophagy Inducers

• Trehalose: mTOR-independent autophagy inducer
• Resveratrol: SIRT1 activator, modulates mTOR
• Metformin: AMPK activator, indirectly reduces mTORC1
• Lithium: Autophagy enhancer via IMPase inhibition

Neuroprotective Strategies

• Combination Therapy: mTOR inhibitors with autophagy inducers
• Temporal Regulation: Intermittent dosing to avoid side effects
• Targeted Delivery: Nanoparticle-based brain delivery
• Biomarker Monitoring: Track p-S6 levels for response

Animal Models

Knockout Models

• Mlst8 Constitutive Knockout: Viable with mild metabolic phenotypes
• Conditional Neuronal Knockout: Leads to impaired synaptic function
• Muscle-specific Knockout: Affects metabolism and function

Transgenic Models

• MLST8 Overexpression: Accelerates tumor growth
• mTORC1 Activation: Phenocopies TSC deficiency

Interaction Network

MLST8 interacts with multiple proteins:

Core mTOR Complex Partners

• mTOR: Kinase catalytic subunit
• RAPTOR: mTORC1-specific scaffolding protein
• RICTOR: mTORC2-specific scaffolding protein
• mLST8: Same protein (homodimerization)

Downstream Effectors

• S6K1 (RPS6KB1): Phosphorylation target
• 4E-BP1 (EIF4EBP1): Translation repressor
• AKT (PKB): Phosphorylation by mTORC2
• PKCα: Phosphorylation target

Regulators

• TSC1/TSC2: Rheb GTPase-activating complex
• Rag GTPases: Amino acid sensing
• PRAS40: mTORC1 inhibitor

Clinical Relevance

Biomarkers

• Phospho-S6 (Ser240/244): Readout of mTORC1 activity
• Phospho-AKT (Ser473): Readout of mTORC2 activity
• LC3-II: Autophagy flux marker

Clinical Trials

• Rapamycin for Alzheimer's disease (NCT04629443)
• Everolimus for TSC-associated seizures
• AZD8055 for solid tumors (completed)

Research Directions

Emerging Areas

• mTORC1/C2 Specific Targeting: Developing isoform-selective inhibitors
• Age-related mTOR Dysregulation: Understanding circadian regulation
• [Blood-Brain Barrier](/entities/blood-brain-barrier) Penetration: Improving drug delivery
• Personalized Medicine: Genetic stratification for treatment

Unresolved Questions

• Optimal dosing regimens for neurodegenerative diseases
• Long-term safety of chronic mTOR inhibition
• Biomarkers for treatment response
• Combination therapy protocols

History

The discovery of MLST8 as an mTOR component followed the identification of mTOR itself:

• 1991: mTOR identified as the target of rapamycin
• 1994: mTORC1 and mTORC2 complexes characterized
• 2002: MLST8 identified as shared component
• 2007: Crystal structure of mTOR kinase domain solved
• 2010s: mTOR roles in neurodegeneration extensively studied

See Also

• [mTOR Gene](/proteins/mtor-protein) - Master kinase regulator
• [RAPTOR Protein](/proteins/raptor-protein) - mTORC1 specific subunit
• [RICTOR Protein](/proteins/rictor-protein) - mTORC2 specific subunit
• [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway) - Complete pathway
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway) - Protein clearance
• [Alzheimer's Disease](/diseases/alzheimers-disease) - Disease association
• [Parkinson's Disease](/diseases/parkinsons-disease) - Disease association
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - Disease association

Background

The study of Lamtor2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [NCBI Gene MLST8](https://www.ncbi.nlm.nih.gov/gene/84916)
• [UniProt Q9BVA0](https://www.uniprot.org/uniprotkb/Q9BVA0)
• [HGNC: MLST8](https://www.genenames.org/data/hgnc_data.php?hgnc_id=29789)
• [Gene Ontology: MLST8](https://amigo.geneontology.org/amigo/term/GO:0005829)

References